Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.

Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H.

Clin Pharmacokinet. 2019 Sep;58(9):1103-1129. doi: 10.1007/s40262-019-00764-2. Review.

PMID:
31049868
2.

An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome.

van Rensburg R, Decloedt EH.

Psychopharmacol Bull. 2019 Feb 15;49(1):84-91.

PMID:
30858642
3.

Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.

Decloedt EH, Sinxadi PZ, van Zyl GU, Wiesner L, Khoo S, Joska JA, Haas DW, Maartens G.

J Antimicrob Chemother. 2019 Mar 1;74(3):699-709. doi: 10.1093/jac/dky481.

PMID:
30535366
4.

Students shooting videos to learn pharmacology.

Decloedt EH, van Schalkwyk S.

Clin Teach. 2019 Oct;16(5):490-496. doi: 10.1111/tct.12963. Epub 2018 Nov 13.

PMID:
30421512
5.

Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial.

Cluver CA, Hannan NJ, van Papendorp E, Hiscock R, Beard S, Mol BW, Theron GB, Hall DR, Decloedt EH, Stander M, Adams KT, Rensburg M, Schubert P, Walker SP, Tong S.

Am J Obstet Gynecol. 2018 Oct;219(4):388.e1-388.e17. doi: 10.1016/j.ajog.2018.07.019. Epub 2018 Jul 26.

PMID:
30055127
6.

Paediatric antimicrobial use at a South African hospital.

Koopmans LR, Finlayson H, Whitelaw A, Decloedt EH, Dramowski A.

Int J Infect Dis. 2018 Sep;74:16-23. doi: 10.1016/j.ijid.2018.05.020. Epub 2018 Jun 20.

7.

Evaluation of the Effectiveness of Dose Individualization to Achieve Therapeutic Vancomycin Concentrations.

Abulfathi AA, Chirehwa M, Rosenkranz B, Decloedt EH.

J Clin Pharmacol. 2018 Sep;58(9):1134-1139. doi: 10.1002/jcph.1254. Epub 2018 May 10.

PMID:
29746714
8.

Therapeutic drug monitoring of amlodipine and the Z-FHL/HHL ratio: Adherence tools in patients referred for apparent treatment-resistant hypertension.

Jones ESW, Lesosky M, Blockman M, Castel S, Decloedt EH, Schwager SLU, Sturrock ED, Wiesner L, Rayner BL.

S Afr Med J. 2017 Sep 22;107(10):887-891. doi: 10.7196/SAMJ.2017.v107i10.12268.

9.

Adding a brief self-report cognitive tool to the IHDS improves effectiveness of identifying patients with HIV-associated dementia in South Africa.

Gouse H, Casson-Crook M, Decloedt EH, Joska JA, Thomas KGF.

J Neurovirol. 2017 Oct;23(5):686-695. doi: 10.1007/s13365-017-0551-y. Epub 2017 Jul 26.

PMID:
28748448
10.

A preliminary review of warfarin toxicity in a tertiary hospital in Cape Town, South Africa.

Jacobs A, Bassa F, Decloedt EH.

Cardiovasc J Afr. 2017 Nov/Dec 23;28(6):346-349. doi: 10.5830/CVJA-2017-029. Epub 2017 May 21.

11.

Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.

Rabie H, Decloedt EH, Garcia-Prats AJ, Cotton MF, Frigati L, Lallemant M, Hesseling A, Schaaf HS.

Expert Opin Pharmacother. 2017 Apr;18(6):589-598. doi: 10.1080/14656566.2017.1309023. Epub 2017 Mar 27. Review.

PMID:
28346018
12.
13.

Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium.

Decloedt EH, Freeman C, Howells F, Casson-Crook M, Lesosky M, Koutsilieri E, Lovestone S, Maartens G, Joska JA.

Medicine (Baltimore). 2016 Nov;95(46):e5401.

14.

Is HIV-1C a risk factor for protease inhibitor failure?

van Zyl GU, Decloedt EH.

Lancet HIV. 2016 Apr;3(4):e149-51. doi: 10.1016/S2352-3018(16)00040-0. Epub 2016 Mar 14. No abstract available.

PMID:
27036986
15.

The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.

Decloedt EH, van der Walt JS, McIlleron H, Wiesner L, Maartens G.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1194-6. doi: 10.5588/ijtld.15.0044.

16.

Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Decloedt EH, Rosenkranz B, Maartens G, Joska J.

Clin Pharmacokinet. 2015 Jun;54(6):581-98. doi: 10.1007/s40262-015-0257-3.

PMID:
25777740
17.

Neuronal toxicity of efavirenz: a systematic review.

Decloedt EH, Maartens G.

Expert Opin Drug Saf. 2013 Nov;12(6):841-6. doi: 10.1517/14740338.2013.823396. Epub 2013 Jul 29. Review.

PMID:
23889591
18.

Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.

Zhang C, Denti P, Decloedt EH, Ren Y, Karlsson MO, McIlleron H.

Br J Clin Pharmacol. 2013 Nov;76(5):741-51. doi: 10.1111/bcp.12101.

19.

The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.

Decloedt EH, Mwansa-Kambafwile J, van der Walt JS, McIlleron H, Denti P, Smith P, Wiesner L, Rangaka M, Wilkinson RJ, Maartens G.

Int J Tuberc Lung Dis. 2013 Mar;17(3):333-5. doi: 10.5588/ijtld.12.0427.

20.

The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.

Decloedt EH, Maartens G, Smith P, Merry C, Bango F, McIlleron H.

PLoS One. 2012;7(3):e32173. doi: 10.1371/journal.pone.0032173. Epub 2012 Mar 7.

21.

Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.

Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G.

Antimicrob Agents Chemother. 2011 Jul;55(7):3195-200. doi: 10.1128/AAC.01598-10. Epub 2011 May 2.

22.

Current trends in drug treatment of obsessive-compulsive disorder.

Decloedt EH, Stein DJ.

Neuropsychiatr Dis Treat. 2010 May 25;6:233-42.

Supplemental Content

Loading ...
Support Center